EBCTCG
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Phase meta-analysisN = 21,457
- Population
- Early breast cancer; the results recorded here are for estrogen-receptor-positive disease (n=10,645)
- Design
- Collaborative meta-analysis of individual patient data from 20 trials (n=21,457) of about 5 years of tamoxifen versus no adjuvant tamoxifen, with about 80% compliance; recurrence and death rate ratios from log-rank analyses by allocated treatment
- Arms
- About 5 years of tamoxifen (experimental): About 5 years of adjuvant tamoxifen
- No adjuvant tamoxifen (control): No adjuvant tamoxifen
- People
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Early Breast Cancer Trialists' Collaborative Group
Any first recurrenceHR 0.53Any first recurrenceHR 0.68Any first recurrenceHR 0.97Breast cancer mortalityHR 0.71Breast cancer mortalityHR 0.66Breast cancer mortalityHR 0.68
Show the numbers
| Endpoint | Analysis | About 5 years of tamoxifen | No adjuvant tamoxifen | Effect |
|---|---|---|---|---|
| Any first recurrenceER-positive disease (n=10,645), years 0-4 | long term-updateEarly 2011 | — | — | HR 0.53P<0.00001Rate ratio (RR) from a log-rank analysis, not a hazard ratio; the abstract gives a standard error of 0.03, not a confidence interval. |
| Any first recurrenceER-positive disease (n=10,645), years 5-9 | long term-updateEarly 2011 | — | — | HR 0.68P<0.00001Rate ratio from a log-rank analysis, not a hazard ratio; standard error 0.06 (no confidence interval in abstract). |
| Any first recurrenceER-positive disease (n=10,645), years 10-14 | long term-updateEarly 2011 | — | — | HR 0.97Rate ratio from a log-rank analysis, not a hazard ratio; standard error 0.10. |
| Breast cancer mortalityER-positive disease (n=10,645), years 0-4 | long term-updateEarly 2011 | — | — | HR 0.71Rate ratio, standard error 0.05; the abstract gives p<0.0001 for the extra mortality reduction in each separate period. |
| Breast cancer mortalityER-positive disease (n=10,645), years 5-9 | long term-updateEarly 2011 | — | — | HR 0.66Rate ratio, standard error 0.05. |
| Breast cancer mortalityER-positive disease (n=10,645), years 10-14 | long term-updateEarly 2011 | — | — | HR 0.68Rate ratio, standard error 0.08. |
| Endpoint | Analysis | About 5 years of tamoxifen | No adjuvant tamoxifen | Effect |
|---|---|---|---|---|
| Any first recurrenceER-positive disease (n=10,645), years 0-4 | long term-updateEarly 2011 | — | — | HR 0.53P<0.00001Rate ratio (RR) from a log-rank analysis, not a hazard ratio; the abstract gives a standard error of 0.03, not a confidence interval. |
| Any first recurrenceER-positive disease (n=10,645), years 5-9 | long term-updateEarly 2011 | — | — | HR 0.68P<0.00001Rate ratio from a log-rank analysis, not a hazard ratio; standard error 0.06 (no confidence interval in abstract). |
| Any first recurrenceER-positive disease (n=10,645), years 10-14 | long term-updateEarly 2011 | — | — | HR 0.97Rate ratio from a log-rank analysis, not a hazard ratio; standard error 0.10. |
| Breast cancer mortalityER-positive disease (n=10,645), years 0-4 | long term-updateEarly 2011 | — | — | HR 0.71Rate ratio, standard error 0.05; the abstract gives p<0.0001 for the extra mortality reduction in each separate period. |
| Breast cancer mortalityER-positive disease (n=10,645), years 5-9 | long term-updateEarly 2011 | — | — | HR 0.66Rate ratio, standard error 0.05. |
| Breast cancer mortalityER-positive disease (n=10,645), years 10-14 | long term-updateEarly 2011 | — | — | HR 0.68Rate ratio, standard error 0.08. |